Anti-Obesity Drugs Market Size & Share 2024-2032

Anti-Obesity Drugs Market Size

The global anti-obesity drugs market size was valued at around USD 5.6 billion in 2023 and is estimated to grow at 27% CAGR from 2024 to 2032. Anti-obesity drugs are prescription medicines that modify physiological processes linked to hunger, metabolism, and nutrient absorption in order to help people lose weight and manage their obesity. These medications may increase metabolism, reduce appetite or inhibit the fat absorption, among others.

The increasing prevalence of obesity and related health issues are the key factors driving the growth of the market. For instance, a report from the World Health Organization (WHO) estimated that, in 2022, one in eight people suffered from obesity globally. Further, 2.5 billion adults aged 18 and above suffered from obesity, were as 890 million cases classified as obese. Additionally, 37 million children below the age of five were overweight. Thus, this highlights the growing need for effective solutions such as anti-obesity drugs, which help individuals to maintain their weight, improve their health, and tackle the global obesity problem.

Additionally, the obesity epidemic has become worse by various factors such as sedentary lifestyle, easy availability of high calories meals, thus necessitating the use of supplementary medical intervention.
 

Additionally, government regulations and guidelines play a vital role in shaping the anti-obesity drugs market, by ensuring safety and efficiency of medicine. For instance, initiatives such as the FDA Fast Track Designation for weight management medications are accelerating the need for new drug approvals. These regulations also assist in the research innovation, escalating the development of advanced treatments. Thus, technological innovations such as personalized medicine, AI-driven drug discovery, are fueling the creation for more effective and targeted anti-obesity drugs.
 

Anti-Obesity Drugs Market Trends

• The market for anti-obesity drugs is evolving with the advancement of technology, allowing for the better drugs production. Drug discovery and development are greatly enhanced by the use of artificial intelligence in healthcare and machine learning.
   
• AI-designed compounds have demonstrated the potential use of AI to provide more effective medicines by successfully activating two receptors involved in weight management, positively showcasing the potential of AI in making more effective targeted therapies.
   
• In addition, the innovative new drug delivery methods have also transformed the market. Advanced delivery techniques such as extended release formulations and  injectable solutions, increase patient compliance and medication effectiveness.
   
• For instance, in November 2023, FDA approved Zepbound injection which is used for chronic weight management in adults having obesity. Clinical trials had demonstrated that individuals using Zepbound has lost an average weight of 18% of their body weight.
   
• Moreover, the combination medicines have also benefited the market which influences the dual mechanisms of action for enhanced weight loss. For example, drugs such as Contrave, a combination of naltrexone and bupropion effectively suppress appetite to support the weight management, which is contributing to the market growth.
   

Anti-Obesity Drugs Market Analysis

Based on product, the market is bifurcated into prescription drugs and OTC drugs. The global market was estimated at USD 5.6 billion in 2023. The prescription drugs segment held revenue of USD 4.1 billion in 2023 and the segment is poised for significant growth at a CAGR of 27.1% during the forecast period.
 

• Prescription drugs play a vital role in the market by offering effective weight management options under medical guidance. These medications focus on the treatment of obesity mechanism such as hunger, fat absorption, metabolic rates, making them more effective treatment options than OTC drugs.
   
• Additionally, these drugs are formed to address specific individual needs, often based on healthcare providers evaluation of particular individuals’ health conditions such as BMI, comorbidities, and other risk factors. For instance, according to the estimates, obesity affects approximately 42% of adults in U.S., creating the demand for clinically proven medication to treat obesity.
   
• In parallel, clinical studies have also shown significant improvement in weight loss up to 15% to 20% in patient by using Semaglutide and Trizepatide drugs.
   
• Furthermore, prescription medication formulations require various clinical testing and regulatory approvals, ensuring their safety and efficacy. With the support of  health providers to monitor the progress and the side effects associated with the drugs, thus these medications offer reliable option for long term obesity management and accelerating the growth of the market.

Learn more about the key segments shaping this market

Download Free PDF

Based on action pathway, the anti-obesity drugs market is bifurcated into peripherally acting drugs and centrally acting drugs. The centrally acting drugs segment accounted for a revenue share of 63.6% and with revenue of USD 3.5 billion in 2023.
 

• The central acting drugs have substantial potential in the anti-obesity market, by targeting the brain’s appetite control centers to regulate hunger and satiety.
   
• These medications act at the level of neurotransmitters which includes dopamine, norepinephrine, and serotonin to minimize food cravings and increase feeling of food fluffiness, which help individuals to maintain their weight and calorie intake more effectively.
   
• For instance, according to data from clinical trials, medicines such as Phentermine-Topiramate and Naltrexone-Bupropion have shown positive result in undergoing weight loss of individuals, up to 5% to 10% of their total body weight.
   
• Additionally, the rising incidence of obesity and its related health complications has increased the need for effective treatments, promoting research and development efforts to specifically focused on centrally acting medications.
   

Based on distribution channel, the anti-obesity drugs market is segmented into retail pharmacies, e-commerce, drug stores, and hospital pharmacies. The retail pharmacies segment held the largest revenue of USD 2.3 billion in 2023.
 

• The dominance of this segment is largely attributed due to its widespread accessibility, retail pharmacies are broadly available, making it an easier way for patients to obtain medicine without a need of doctor’s prescription. This is specifically benefited for those patients living in remote or underserved areas.
   
• Retail pharmacies also educate patients about the anti-obesity medications, their side effects and proper usage. They also provide personalized counselling, helping patients to know the difference between the OTC drugs and prescription drugs for weight loss.
   
• Furthermore, these pharmacies also offer services such as extended operating hours and nearby locations, which improves patient adherence to treatment regimens, leading to better patient outcomes and also contributing to the market growth.

The North America anti-obesity drugs market is accounted for 2.5 billion revenues in 2023 forecasted to reach USD 21.9 billion by 2032. The U.S. dominated the North America market with the largest revenue of USD 2.3 billion in 2023.
 

• The rising incidence of chronic disorders such as type 2 diabetes, cardiovascular diseases, and obesity are on rise in the U.S., is accelerating the demand for the anti-obesity drugs.
   
• For instance, in 2021, as per the data from the Centers for Disease Control and Prevention (CDC), reports that approximately 38.4 million individuals in U.S. suffered from diabetes, about which 90% to 95 % individuals suffered from type 2 diabetes, resulting for about 11.6% of the total global population.
   
• Moreover, the rise in obesity is also influenced by cultural and lifestyle factors which includes the availability of high calorie food, sedentary habits, further contributing to the obesity cases, which underscores the need for effective treatment option such as weight loss medication.
   

Europe: Anticipate significant growth in UK’s anti-obesity drugs market from 2024 to 2032.
 

• The growth of anti-obesity market in this region is anticipated to be bolstered by the UK governments commitment towards tacking obesity via initiatives such as public health campaigns, regulatory measures aiming towards unhealthy food marketing, and guidelines that promoting the healthier lifestyle, is contributing to the market growth.
   
• For instance, according to the health survey conducted by government of England estimates that in 2021, 25.9% of individuals were obese and 37.9% were overweight, of total population.
   
• To tackle this issue, the government of UK has launched a Euro 40 million pilot program to increase the accessibility of weight loss treatment for patients, outside the hospital.
   

Asia pacific: Japan anti-obesity drugs market is poised for substantial growth between 2024 and 2032.
 

• The rising incidence of obesity and obesity-related health disorder such as type 2 diabetes and cardiovascular disease,  thereby accelerating the market growth. 
   
• For instance, according to the report from Internation Diabetes Federation (IDF), estimates that in 2021, 11,004,999 individuals were diabetic, which is 11.8% of total the population.
   
• Thus, this demographic shift has created awareness among the healthcare providers and policymakers for the need of effective strategies to come over the obesity and its related health conditions.
   
• Further, Japan also has leading pharmaceutical companies which has great capabilities in drug development such as anti-obesity medications.
   

Middle East and Africa: Expect noteworthy growth in Saudi Arabia's anti-obesity drugs market from 2024 to 2032.
 

• Saudi Arabia’s advance healthcare infrastructure and rising investment in advanced healthcare technologies create opening for the development and adoption of advanced anti-obesity medicine tailored to the country’s patient specific needs.
   
• Further, the growing case of obesity is creating the heightened demand for  anti-obesity drugs in Saudi Arabia.
   

For instance, according to the data from National Institute of Health (NIH), in 2023, one fifth of the population was overweight or obese, which is 9.4%. The rising obesity cases was highest among children aged between 2 to 6 years is 12.3%, which was highest among boys, 10.4% than girls, 8.3%.
 

Anti-Obesity Drugs Market Share

The top 4 players of the anti-obesity market account for approximately 55% of the market share which includes companies such as Eli Lily & Co, Novo Nordisk A/S, Pfizer Inc., Rhythm Pharmaceuticals, Inc, among others. Moreover, strategic partnerships with pharmaceutical companies, research institutes, and government agencies play a primary role in advancing the development of medications and getting the necessary permits. The development of public awareness about obesity and its health impact through the social media platform, will encourage more individuals to seek the treatment, enabling market players to strengthen their position in this growing sector.
 

Anti-Obesity Drugs Market Companies

Some of the eminent market participants operating in the anti-obesity drugs industry include:

• Arena Pharmaceuticals, Inc.
• AstraZeneca PLC
• Boehringer Ingelheim International GmbH
• Currax Pharmaceuticals LLC
• Eli Lily & Co
• F. Hoffmann-La Roche Ltd
• Gelesis
• GlaxoSmithKline plc
• Merck & Co., Inc.
• Novartis AG
• Novo Nordisk A/S
• Orexigen Therapeutics, Inc.
• Pfizer Inc.
• Rhythm Pharmaceuticals, Inc.
• Vivus, Inc.
   
• Novo Nordisk A/S has strong geographical presence which enables it to boost its market reach. Novo Nordisk A/S operates in more than 170 countries thus comprising of a strong distribution network.
   
• Pfizer is continuously investing in research & development, fostering innovation and growth. The company is developing Danuglipron, an oral obesity drug which is in phase 2 clinical trial, offering a convenient alternative option for the injectable treatment.
   
• Eli Lily is leading in the development of multi-receptor agonist, which target GLP -1 ang GLP pathways such as Tirezpatide, which benefits in weight loss, thereby strengthening the company’s product portfolio.
   

Anti-Obesity Drugs Industry News:

• In February 2024, Eli Lilly & Co launched Mounjaro, in India, targeting the country’s high obesity cases and incidence related to diabetes. This move has reflected Eli Lilly’s commitment in expanding it market reach in the anti-obesity market.
   
• In December 2024,  Rhythm Pharmaceuticals, Inc has announced that U.S. FDA had approved IMCIVREE (Setmelanotide) for patients for 2 years old to reduce excess body weight and to maintain body weight reduction for long term. This approval strengthened the company’s product portfolio.
   

The anti-obesity drugs market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Prescription drugs
• OTC drugs

Market, By Action Pathway

• Peripherally acting drugs
• Centrally acting drugs

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Drug stores
• E-commerce

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE